Thor Medical A

Thor Medical A FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Thor Medical A (TRMED.OL) as of Oct 16, 2026 is 207.97 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 56.39 % — a change of 268.82% (higher).

FCF Conversion

207.97 %

YoY

268.82%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Thor Medical A is 2025 207.97 % . FCF Conversion Rate (FCF/EBITDA) of Thor Medical A was 2024 56.39 % . It decreases by 268.82% higher compared to the previous year.

The Thor Medical A FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
97.34 NOK
Jan 1, 2019
94.95 NOK
Jan 1, 2020
95.52 NOK
Jan 1, 2021
91.48 NOK
Jan 1, 2022
133.24 NOK
Jan 1, 2023
241.29 NOK
Jan 1, 2024
56.39 NOK
Jan 1, 2025
207.97 NOK
The Thor Medical A FCF Conversion history
YEARFCF ConversionYoY
207.97 %+268.82%
56.39 %-76.63%
241.29 %+81.09%
133.24 %+45.65%
91.48 %-4.23%
95.52 %+0.60%
94.95 %-2.46%
97.34 %+13.52%
85.75 %-1.72%
87.25 %-0.94%
88.08 %-6.19%
93.89 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Thor Medical A Stock analysis

What does Thor Medical A do? Nordic Nanovector ASA is a Norwegian biopharmaceutical company specializing in the development and commercialization of therapies for the treatment of lymphoma and other cancers. The company was founded in 2009 by a group of leading scientists in the field of cancer research, focused on developing new and innovative treatment options for cancer. Nordic Nanovector's business model is based on the use of antibodies specifically targeted to cancer cells. An example of this is the drug Betalutin, which contains a radioactive substance that selectively destroys cancer cells. Betalutin has been tested in multiple clinical trials and has shown promising results in the treatment of non-Hodgkin lymphoma. In addition to Betalutin, the company also has another technology platform based on the use of antibodies with high affinity to specific types of cancer. Nordic Nanovector also manufactures a wide range of diagnostic tools that can be used in cancer research. Since its inception, Nordic Nanovector has received numerous national and international awards and prizes for its innovative products and technologies. The company has established relationships with various academic institutions and organizations to advance research and development. In addition to product development, the company has undergone an impressive capital raise to advance the development of these therapies. Nordic Nanovector has received several public and private financings in recent years to support and expand its research activities. In 2015, the company went public on the Oslo Stock Exchange, foregoing the conquest of the US market. The foundation of the company's portfolio is protected by technology patents and product patents. The company has undergone several challenging development and approval steps to gain a competitive advantage over competitors. The goal is to promote long-term growth and availability of the products worldwide. Nordic Nanovector believes that its business model is realized based on innovative technologies in cancer research. With a focus on the development of therapies and diagnostic tools, the company has built significant potential in the industry. The future prospects and growth outlook are positive and are expected to contribute to even greater success for Nordic Nanovector in the future. Thor Medical A is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Thor Medical A stock

FCF Conversion Rate (FCF/EBITDA) of Thor Medical A is 207.97 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Thor Medical A changed from 56.39 % to 207.97 %, representing a 268.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Thor Medical A since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Thor Medical A with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Thor Medical A

All Key Metrics — Thor Medical A